Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at Oxford University have received a prestigious Wellcome Innovator Grant for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in human consciousness.

The study is a collaboration between Neurosurgery (Associate Professor Alex Green at the Nuffield Department of Surgical Sciences, NDS), Engineering (Professor Tim Denison at the Department of Engineering Science and the MRC Brain Network Dynamics Unit), and Neurology (Dr Damian Jenkins at the Nuffield Department of Clinical Neurosciences). It builds on pilot data from Dr Alceste Deli who, during her DPhil, has shown that PPN stimulation can alter sleep and arousal states.

The project will involve a 10-subject first-in-man clinical trial of PPN stimulation in patients with minimally conscious state (MCS) following brain injury (trauma or stroke) and will involve further development of a Deep Brain Stimulation investigational system called the ‘Picostim-DyNeuMo’ that was developed in a strategic collaboration between Professor Denison and Bioinduction, Ltd, a UK-based company developing implantable medical devices. The Picostim-DyNeuMo embeds instrumentation that enables novel clinical neuroscience using therapeutic neurostimulators.

The research team aim to identify biomarkers that signify arousal state, within the brain and on EEG, and to develop ‘closed-loop’ stimulation patterns that optimise increased arousal and improve sleep. The device will also take into account circadian rhythms that are often disrupted in patients with MCS.

The trial will be supported by the Surgical Intervention Trials Unit (SITU) at NDS (Ms Lucy Davies) and there will be an ethical component led by Professor Julian Savulescu at the Oxford Martin School. Dr Martin Gillies from NDS will also be involved in the running of the project.

The patients in the trial will be implanted with Deep Brain Stimulating electrodes (connected to an Implantable Pulse Generator) into the PPN (brainstem) and signals from the brain (local field potentials), EEG (electroencephalogram) and other signals, such as physical activity, will be used to control the system in a ‘closed loop’ manner. 

The patients in the trial will be implanted with Deep Brain Stimulating electrodes (connected to an Implantable Pulse Generator) into the PPN (brainstem) and signals from the brain (local field potentials), EEG (electroencephalogram) and other signals, such as physical activity, will be used to control the system in a ‘closed loop’ manner.

Similar stories

Prostate cancer AI diagnosis tool begins evaluation in Oxford

New artificial intelligence software that can help to spot prostate cancer is being trialled by researchers at Oxford University Hospitals (OUH) NHS Foundation Trust.

NDS SITU host first ever Surgical Trials Showcase

The first ever showcase of the Surgical Intervention Trials Unit, Nuffield Department of Surgical Sciences (NDS SITU) was hosted on Monday 23 January 2023 at the Richard Doll Building on Old Road Campus, Oxford, and also online.

Mr Gurdeep S. Mannu awarded Cancer Research UK Clinician Scientist Fellowship

Many congratulations to Mr Gurdeep S. Mannu who has been awarded a five-year Cancer Research UK Clinician Scientist Fellowship.

Blog posts

Marathon challenge for Prostate Cancer UK

Runners of all abilities started 2023 by challenging themselves to run 26.2 miles across January to fundraise for Prostate Cancer UK as part of the charity’s Run the Month: Marathon Edition.

Staff Census: We need you!

All Medical Sciences staff are invited to log into HR self-service and ensure their contact, diversity background and disability details are up to date. Between 6% and 27% of staff in the Division are missing their diversity data which makes it difficult to complete statutory reporting, understand or track our population changes and to plan actions around staff diversity and equality – make sure your data is complete today!

Oxford MedSci goes silver: 10 Years of Athena SWAN

The Medical Sciences Division is celebrating 10 years since its first Athena Swan bronze application, and the first year in which all 16 of its departments have achieved a silver award. The silver award recognises commitment to gender equality, understanding culture and context, and more. Read about our department’s hard work and innovation.